Do your patients understand their risk of having another heart attack?
Do your patients understand why you’ve chosen their treatment regimen, including their oral antiplatelet?
Are your patients aware of how to take their treatment regimen, including their oral antiplatelet?
Do they understand how long they may need to take medications, including their oral antiplatelet, and potential reasons for discontinuation?
Do they know that it’s important to stay on their treatments for as long as their doctor recommends?
Are they aware of what lifestyle modifications they need to make, such as diet, exercise, cardiac rehabilitation, and management of comorbidities?
Are your patients aware of the possible side effects of their medications, including their oral antiplatelet?
Do your patients understand the importance of talking to other physicians about the medications they are taking, including their oral antiplatelet?
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.